FDA panel to consider Avastin for breast cancer; Teva won't make anesthetic drug anymore;

 @FiercePharma: Report: Sanofi inks generics deal with Japanese firm. Article | Follow @FiercePharma

> An FDA advisory panel will meet in July to review two proposed new uses for Roche's blockbuster cancer drug Avastin in patients with advanced breast cancer. Report

> Daiichi Sankyo's incoming CEO Joji Nakayama said he's confident a ban imposed by U.S. regulators on some drugs from its Indian unit, Ranbaxy Laboratories, will be lifted. Report

> The founding families of many of India's drug companies want to sell their businesses, finding that it is difficult to grow them by relying mainly on selling generic versions of medicines, said the former owner of Ranbaxy Laboratories. Report

> Israel-based Teva Pharmaceutical Industries said it will spend $56 million to expand a Canadian production plant. Report

> Paul Bisaro, the CEO of Watson Pharmaceuticals, filed papers in federal court accusing the Federal Trade Commission of abusing its power in attempting to stop pay-for-delay deals, which the agency argues are anti-competitive and harmful to consumers. Report

> Shire Pharmaceuticals is buying four laboratory buildings in Raytheon's former Lexington, Mass., campus for more than $200 million. Report

Biotech News

 @FierceBiotech:  InterMune to chop 60 workers in wake of FDA's rejection. Article | Follow @FierceBiotech

 @JohnCFierce: Schwan on biosimilars: "It's a different ball game and we expect a much lesser penetration of biosimilars." Follow @JohnCFierce

> After lengthy delay, BMS plans starring ASCO role for melanoma drug. Item

> FDA panel offers unanimous endorsement of Theratech's HIV drug. Story

> Venter: Synthetic cells will revolutionize vax development. Item

> GSK tries an open-source strategy for drug development. Story

And Finally... Modifying drugs to enhance the time they remain bound to their targets, or residence time, may lead to better diagnostic and therapeutic agents, a new study suggests. Report